Please turn JavaScript on
header-image

American Market News

Want to know the latest news and articles posted on American Market News?

Then subscribe to their feed now! You can receive their updates by email, via mobile or on your personal news page on this website.

See what they recently published below.

Website title: American Market News

Is this your feed? Claim it!

Publisher:  Unclaimed!
Message frequency:  45 / week

Message History

William Blair assumed coverage on shares of Coterra Energy (NYSE:CTRA – Free Report) in a report released on Wednesday morning, Marketbeat.com reports. The brokerage issued an outperform rating and a $36.00 target price on the stock. Several other analysts also recently commented on the stock. Weiss Ratings reiterated a “hold (c-)” rating on shares of […]

Read full story

Maple Leaf Foods (TSE:MFI – Get Free Report) received a C$33.00 price target from Royal Bank Of Canada in a note issued to investors on Thursday,BayStreet.CA reports. The firm currently has an “outperform” rating on the stock. Royal Bank Of Canada’s price target would indicate a potential upside of 30.38% from the company’s previous close. […]

Read full story

Rothschild Redb upgraded shares of Saia (NASDAQ:SAIA – Free Report) to a hold rating in a report published on Wednesday morning,Zacks.com reports. Several other equities research analysts have also issued reports on the company. JPMorgan Chase & Co. dropped their price objective on Saia from $360.00 to $346.00 and set an “overweight” rating for the […]

Read full story

Empire (TSE:EMP.A – Get Free Report) had its target price lowered by equities research analysts at National Bankshares from C$59.00 to C$58.00 in a research note issued to investors on Thursday,BayStreet.CA reports. The brokerage presently has a “sector perform” rating on the stock. National Bankshares’ price objective would indicate a potential upside of...

Read full story

Leerink Partnrs upgraded shares of Compass Therapeutics (NASDAQ:CMPX – Free Report) to a strong-buy rating in a research report report published on Wednesday morning,Zacks.com reports. Leerink Partnrs also issued estimates for Compass Therapeutics’ Q2 2026 earnings at ($0.10) EPS and Q4 2026 earnings at ($0.11) EPS. A number of other equities analysts also recently i...

Read full story